Treatment-Related Adverse Events of Antibody Drug Conjugates Identified
MONDAY, Nov. 21, 2022 (HealthDay News) — Adverse effects associated with antibody-drug conjugates (ADCs) have been described in a review and meta-analysis published online Nov. 21 in Cancer.Youwen Zhu, from Central South University in Changsha, China…
Learn MoreFDA Approves First Drug to Delay Onset of Type 1 Diabetes
FRIDAY, Nov. 18, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the first drug that could delay the development of type 1 diabetes (T1D).Teplizumab (Tzield) targets the autoimmune issues that drive the disease, rat…
Learn MoreShe Thought Cancer Had Won — Until This Experimental Therapy
FRIDAY, Nov. 11, 2022 (HealthDay News) — The breast cancer of author and poet Stephanie Gangi has receded and advanced in wearying waves for two decades now.First diagnosed and treated in 1999, Gangi’s cancer spread to the bone of her sternum in 2014…
Learn MoreTreatment Sequence Studied for Advanced BRAF-Mutant Melanoma
THURSDAY, Oct. 6, 2022 (HealthDay News) — For patients with treatment-naive BRAFv600 mutant metastatic melanoma, treatment first with combination nivolumab/ipilimumab yields better overall survival than dual BRAF/MEK inhibition with dabrafenib/tramet…
Learn MoreUn nuevo método de tratamiento mejora las probabilidades contra 2 tipos de cáncer de piel
JUEVES, 15 de septiembre de 2022 (HealthDay News) — Parece que a los pacientes con un cáncer de piel les va mejor si reciben inmunoterapia antes de la extirpación quirúrgica de su cáncer, muestran dos ensayos clínicos.De hecho, a algunos les va tan b…
Learn MoreEn un pequeño estudio, la terapia de T con RAQ lleva el lupus a la remisión
JUEVES, 15 de septiembre de 2022 (HealthDay News) — Aunque el lupus no tiene cura y los tratamientos no funcionan en muchas de los 1.5 millones de personas que viven con la enfermedad en Estados Unidos, un nuevo estudio muestra que una terapia contra…
Learn MoreIn Small Study, CAR-T Therapy Pushes Lupus Into Remission
THURSDAY, Sept. 15, 2022 (HealthDay News) — While there’s no cure for lupus and treatments don’t work for many of the 1.5 million people who live with the disease in the United States, a new study shows a cancer therapy may kick hard-to-treat lupus i…
Learn MoreNew Treatment Approach Boosts Odds Against 2 Types of Skin Cancer
THURSDAY, Sept. 15, 2022 (HealthDay News) — Skin cancer patients appear to fare better if they receive immunotherapy before their cancers are surgically removed, a pair of clinical trials show.In fact, some do so well that their immune system essenti…
Learn MoreAdjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
WEDNESDAY, Sept. 14, 2022 (HealthDay News) — Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy r…
Learn MoreEfficacy of Durvalumab for Early-Stage TNBC Examined by Race
FRIDAY, Aug. 19, 2022 (HealthDay News) — Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African …
Learn More